Riferimento:
Clin Nucl Med. 2012 Sep;37(9):892-4.
Autori:
Naswa N, Karunanithi S, Soundararajan R, Das KJ, Agarwal KK, Malhotra A, Bal C, Kumar R.
Fonte:
Clin Nucl Med. 2012 Sep;37(9):892-4.
Anno:
2012
Azione:
Tumore neuroendocrino del pancreas con metastasi epatiche e scheletriche confermate con immagini convenzionali sottoposto a 68Ga-DOTANOC PET/CT.
Target:
68Ga-DOTANOC PET-CT/tumore neuroendocrino del pancreas.
ABSTRACT
PET/CT imaging using Ga-labeled somatostatin analogs has become a popular noninvasive diagnostic modality in the workup of patients with neuroendocrine tumors. A 65-year-old man with pancreatic neuroendocrine tumor with confirmed liver metastases on conventional imaging underwent restaging Ga-DOTANOC PET/CT to monitor response to cold octreotide therapy. Previous PET/CT had shown presence of multiple liver and skeletal metastases along with a primary pancreatic tumor showing intense tracer uptake. The present PET/CT study showed an increase in number and uptake of the metastatic lesions suggestive of progressive disease resulting in the appearance of a superscan.
Sostanze: